Tag: mCRC

Amgen’s Lumakras shows promise in phase 3 lung cancer study

Amgen has shared positive results from a late-stage study evaluating its KRAS inhibitor, Lumakras (sotorasib), in certain lung cancer patients. The phase 3 CodeBreaK 200 trial compared Lumakras to docetaxel chemotherapy in patients with previously treated, locally advanced and unresectable or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). New data…

Continue Reading Amgen’s Lumakras shows promise in phase 3 lung cancer study

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 04, 2023–(BUSINESS WIRE)–Bristol…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | News

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 4, 2023– Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with…

Continue Reading Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer | News

Design and Goals of the Phase 3 MOUNTAINEER-03 Study in mCRC

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, medical oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study (NCT05253651). In the global, open label, randomized, study,…

Continue Reading Design and Goals of the Phase 3 MOUNTAINEER-03 Study in mCRC

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance PALO ALTO, Calif., May 31, 2023–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data…

Continue Reading Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced three-year (36.5 months minimum; 44.0 months median) follow-up results from the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits with the…

Continue Reading Exelixis (EXEL) and Bristol Myers Squibb (BMY) Reports Strong Results from Phase 3 CheckMate-9ER Trial

Review of Molecular Testing Options in Metastatic Colorectal Cancer

Expert oncologists review key updates regarding metastatic colorectal cancer from recent meetings and discuss their implications on real-world clinical practice. At a recent Around the Practice program hosted by CancerNetwork®, experts discussed the use of molecular and genetic testing to better treat patients with metastatic colorectal cancer (CRC). The panel…

Continue Reading Review of Molecular Testing Options in Metastatic Colorectal Cancer

Celyad Oncology Provides Fourth Quarter 2022 Business Update and 2023 Outlook

MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides a fourth quarter 2022 business update and an outlook for 2023. Michel Lussier, interim Chief Executive Officer…

Continue Reading Celyad Oncology Provides Fourth Quarter 2022 Business Update and 2023 Outlook

Acq-GAs in Advanced Colorectal Cancer Patients Receiving Cetuximab-Based First-Line Chemotherapy

The following is a summary of “Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance),” published in the January 2023 issue of Oncology by Raghav, et al. In metastatic colorectal cancer (mCRC), acquired genomic alterations (Acq-GAs), including RAS,…

Continue Reading Acq-GAs in Advanced Colorectal Cancer Patients Receiving Cetuximab-Based First-Line Chemotherapy

Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer

Adding bevacizumab (Avastin) to trifluridine (FTD)/tipiracil (TPI; Lonsurf) yielded improvements in survival and disease control rates (DCRs) among patients with metastatic colorectal cancer (mCRC), according to according to results from the phase 3 SUNLIGHT study (NCT0437187). The survival benefit was consistent across all clinically relevant subgroups, and showed that the…

Continue Reading Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

Continue Reading Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products 2. The design elements of clinical trials for biosimilar drugs are rigorous Evidence Rating Level: 1 (Excellent) Study Rundown: Biologic treatments constitute a large portion of prescription costs in the United States. Biosimilar…

Continue Reading Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

Front-Line Treatment of DLBCL – NewsBreak

Dr. Lenz on the Rationale for the CheckMate 9X8 in Metastatic CRC Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer. Heinz-Josef Lenz, MD, FACP, associate director, Clinical Research, J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director, University of Southern…

Continue Reading Front-Line Treatment of DLBCL – NewsBreak

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

“…ctDNA may be more comprehensive representation of the tumor mutations of an individual patient,” the authors explained. “Longitudinal ctDNA analysis can also provide a molecular profile of how a tumor evolves and changes over time in response to chemotherapy.” They evaluated how the results of ctDNA analysis were associated with…

Continue Reading ctDNA Successfully Detects Mutations With Treatment Implications in mCRC